The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
FINGOLIMOD-TEVA/TE-FINGOLIMOD (Teva Pharma Australia Pty Ltd)
Product name
FINGOLIMOD-TEVA/TE-FINGOLIMOD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
121 (255 working days)
Active ingredients
Fingolimod hydrochloride
Registration type
New generic medicine
Indication
FINGOLIMOD-TEVA/TE-FINGOLIMOD is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.